This article is more than 5 years old. Information may no longer be current.

Preoperative bevacizumab appears to reduce operative complications, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WAILEA, Hawaii — Bevacizumab used preoperatively facilitates surgical management of complex diabetic detachments, a study presented here found.

Because of reduced bleeding, benefits are most notable in complex cases, Maria H. Berrocal, MD, said at the American Society of Retina Specialists annual meeting. The study assessed visual acuity outcomes and the need for postoperative procedures in eyes undergoing pars plana vitrectomy for diabetic retinal detachments pretreated with intravitreal Avastin (bevacizumab, Genentech).

Two groups participated in this prospective study. Forty-eight eyes underwent pars plana vitrectomy either for traction or for traction and rhegmatogenous retinal detachment secondary to diabetic retinopathy. In all cases, 1.25-mg intravitreous bevacizumab was given preoperatively.

Pretreatment resulted in reduced intraoperative and perioperative bleeding, reduced surgery time, reduced postoperative complications and reduced number of postoperative procedures, Dr. Berrocal said.